Jpmorgan Chase & CO Abeona Therapeutics Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ABEO
# of Institutions
61Shares Held
28MCall Options Held
757KPut Options Held
44.5K-
Suvretta Capital Management, LLC New York, NY3.69MShares$22.9 Million0.92% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.47MShares$21.5 Million0.98% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.25MShares$20.1 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.68MShares$16.6 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.01MShares$12.4 Million0.0% of portfolio
About ABEONA THERAPEUTICS INC.
- Ticker ABEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,950,380
- Market Cap $36.9M
- Description
- Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...